IL33659A - Nucleotides that cause interferon formation - Google Patents
Nucleotides that cause interferon formationInfo
- Publication number
- IL33659A IL33659A IL33659A IL3365970A IL33659A IL 33659 A IL33659 A IL 33659A IL 33659 A IL33659 A IL 33659A IL 3365970 A IL3365970 A IL 3365970A IL 33659 A IL33659 A IL 33659A
- Authority
- IL
- Israel
- Prior art keywords
- complexed
- interferon
- polymers
- acid
- culture
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title claims description 43
- 108010050904 Interferons Proteins 0.000 title claims description 43
- 229940079322 interferon Drugs 0.000 title claims description 38
- 239000002773 nucleotide Substances 0.000 title claims description 14
- 125000003729 nucleotide group Chemical group 0.000 title claims description 14
- 239000000411 inducer Substances 0.000 title description 2
- 229920000642 polymer Polymers 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 229920005603 alternating copolymer Polymers 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 241001515965 unidentified phage Species 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 229930183912 Cytidylic acid Natural products 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 150000002367 halogens Chemical group 0.000 claims description 2
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 101150054335 DNA-R gene Proteins 0.000 claims 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 claims 1
- 230000002070 germicidal effect Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000004113 cell culture Methods 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 19
- 241000700605 Viruses Species 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 230000006698 induction Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 230000000120 cytopathologic effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 241000711975 Vesicular stomatitis virus Species 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000002799 interferon inducing agent Substances 0.000 description 5
- 229940047124 interferons Drugs 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000007505 plaque formation Effects 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000003837 chick embryo Anatomy 0.000 description 3
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 206010044325 trachoma Diseases 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- HZLHRDBTVSZCBS-UVJJDBRNSA-N 4-[(e)-(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]-2-methylaniline;hydrochloride Chemical compound Cl.C1=CC(=N)C(C)=C\C1=C(C=1C=C(C)C(N)=CC=1)/C1=CC=C(N)C=C1 HZLHRDBTVSZCBS-UVJJDBRNSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101001005711 Homo sapiens MARVEL domain-containing protein 2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 101100536883 Legionella pneumophila subsp. pneumophila (strain Philadelphia 1 / ATCC 33152 / DSM 7513) thi5 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 101100240664 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nmt1 gene Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
- FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 101150084216 thiB gene Proteins 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79212869A | 1969-01-17 | 1969-01-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL33659A0 IL33659A0 (en) | 1970-03-22 |
| IL33659A true IL33659A (en) | 1974-11-29 |
Family
ID=25155886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL33659A IL33659A (en) | 1969-01-17 | 1970-01-05 | Nucleotides that cause interferon formation |
Country Status (12)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2016015B (en) * | 1978-01-22 | 1982-05-06 | Hayashibara Co | Method of preparing interferon and preparations containing interferon |
| JPS5598118A (en) * | 1979-01-18 | 1980-07-25 | Hayashibara Takeshi | Preparation of type-2 interferon and drug containing the same |
-
1969
- 1969-12-04 BR BR214761/69A patent/BR6914761D0/pt unknown
- 1969-12-16 NL NL6918867A patent/NL6918867A/xx unknown
-
1970
- 1970-01-05 IL IL33659A patent/IL33659A/en unknown
- 1970-01-06 IE IE13/70A patent/IE33914B1/xx unknown
- 1970-01-12 GB GB1295684D patent/GB1295684A/en not_active Expired
- 1970-01-13 ES ES375395A patent/ES375395A1/es not_active Expired
- 1970-01-15 DE DE19702001734 patent/DE2001734A1/de active Pending
- 1970-01-16 BE BE744528D patent/BE744528A/xx unknown
- 1970-01-16 ZA ZA700277A patent/ZA70277B/xx unknown
- 1970-01-16 FI FI700132A patent/FI48353C/fi active
- 1970-01-16 FR FR707001577A patent/FR2034473B1/fr not_active Expired
- 1970-01-16 AT AT40670A patent/AT302524B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2034473A1 (enrdf_load_stackoverflow) | 1970-12-11 |
| NL6918867A (enrdf_load_stackoverflow) | 1970-07-21 |
| GB1295684A (enrdf_load_stackoverflow) | 1972-11-08 |
| AT302524B (de) | 1972-10-25 |
| IE33914B1 (en) | 1974-12-11 |
| FI48353B (enrdf_load_stackoverflow) | 1974-05-31 |
| ES375395A1 (es) | 1972-11-01 |
| FR2034473B1 (enrdf_load_stackoverflow) | 1973-07-13 |
| DE2001734A1 (de) | 1970-07-23 |
| BE744528A (fr) | 1970-07-16 |
| IE33914L (en) | 1970-07-17 |
| ZA70277B (en) | 1971-08-25 |
| BR6914761D0 (pt) | 1973-03-08 |
| IL33659A0 (en) | 1970-03-22 |
| FI48353C (fi) | 1974-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hilleman | Prospects for the use of double-stranded ribonucleic acid (poly I: C) inducers in man | |
| US5676974A (en) | Pharmaceutical compositions containing giroxina and phospholipase A2 and methods of increasing a patient's CD4 count using the pharmaceutical compositions | |
| US4130641A (en) | Induction of interferon production by modified nucleic acid complexes | |
| McCuskey et al. | Species differences in Kupffer cells and endotoxin sensitivity | |
| US4473581A (en) | Organogermanium induction of interferon production | |
| US4124702A (en) | Polynucleotides active as inducers of interferon production in living animal cells | |
| FI72143C (fi) | Foerfarande foer framstaellning av maenniskointerferon. | |
| Black et al. | The antiviral activity of certain thiophosphate and 2′-chloro substituted polynucleotide homopolymer duplexes | |
| WO1988008032A1 (en) | Receptor from the small rhinovirus receptor group | |
| IL33659A (en) | Nucleotides that cause interferon formation | |
| US3843629A (en) | Complexs of polyriboinosinic acid and polyribo-2-thiocytidylic acid | |
| KR0128098B1 (ko) | 항hiv제 | |
| Baglioni et al. | The Action of Interferon at the Molecular Level: The unique antiviral defense mechanism of interferon, a substance produced in the body in response to infection, is being studied closely for possible therapeutic applications | |
| Tilles | Diethylaminoethyl-dextran enhancement of interferon induction by a complexed polyribonucleotide | |
| IL29066A (en) | Pharmaceutical preparations containing multi-chain poly-nucleotides to encourage interferon production in humans, animals or cell cultures | |
| EP0292000A1 (en) | Treatment of viral infection | |
| Müller et al. | Dual biological activity of apurinic acid on human lymphocytes: induction of interferon-γ and protection from human immunodeficiency virus infection in vitro | |
| JPH04506074A (ja) | レトロウイルス複製を阻害するαアノマーオリゴヌクレオチド化合物 | |
| Tytell et al. | Interferons and Host Resistance: With Particular Emphasis on Induction by Complexed Polynucleotide | |
| Finkelstein et al. | Interferon--1968. How much do we understand? | |
| Suzuki et al. | Interferon‐Inducing Activity of Acidic Polysaccharides: I. Induction of Rabbit Serum Interferon by Hansenula Phosphomannans | |
| JP3061376B2 (ja) | インフルエンザウィルス感染防御剤 | |
| Campbell et al. | A comparison of the protective effect against Mengo virus infection in mice of interferons induced by polyI: C and Mengo virus | |
| EP0351625B1 (en) | Anti-hiv activity of bv-3608 | |
| Stratton et al. | Cytotoxicity and deoxyribonucleic acid damage associated with bromoacetate |